16: A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy and safety of a single, oral dose of SYM-1219, a granule formulation containing 2 grams of secnidazole, for the treatment of bacterial vaginosis

J. Schwebke; F. Morgan; W. Koltun; H. Pentikis; N. Adetoro; C. Braun

doi:10.1016/j.ajog.2016.09.017

16: A phase 3 randomized, double-blind, placebo-controlled study to confirm the efficacy and safety of a single, oral dose of SYM-1219, a granule formulation containing 2 grams of secnidazole, for the treatment of bacterial vaginosis

American Journal of Obstetrics and Gynecology ◽

10.1016/j.ajog.2016.09.017 ◽

2016 ◽

Vol 215 (6) ◽

pp. S821-S822 ◽

Cited By ~ 4

Author(s):

J. Schwebke ◽

F. Morgan ◽

W. Koltun ◽

H. Pentikis ◽

N. Adetoro ◽

...

Keyword(s):

Oral Dose ◽

Bacterial Vaginosis ◽

Single Oral Dose ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Granule Formulation

Download Full-text

Results of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of astodrimer gel for prevention of recurrent bacterial vaginosis

American Journal of Obstetrics and Gynecology ◽

10.1016/j.ajog.2019.10.087 ◽

2019 ◽

Vol 221 (6) ◽

pp. 672-673 ◽

Cited By ~ 3

Author(s):

J. Schwebke ◽

B. Carter ◽

A. Waldbaum ◽

C. Price ◽

A. Castellarnau ◽

...

Keyword(s):

Bacterial Vaginosis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis

American Journal of Obstetrics and Gynecology ◽

10.1016/j.ajog.2017.08.017 ◽

2017 ◽

Vol 217 (6) ◽

pp. 678.e1-678.e9 ◽

Cited By ~ 17

Author(s):

Jane R. Schwebke ◽

Franklin G. Morgan ◽

William Koltun ◽

Paul Nyirjesy

Keyword(s):

Bacterial Vaginosis ◽

Controlled Study ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Oral Doses

Download Full-text

A phase 3, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the arise trial

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp-2017-316074.63 ◽

2017 ◽

Vol 88 (5) ◽

pp. e1.63-e1 ◽

Cited By ~ 8

Author(s):

David Dodick ◽

Messoud Ashina ◽

David Kudrow ◽

Michel Lanteri-Minet ◽

Vera Osipova ◽

...

Keyword(s):

Controlled Study ◽

Migraine Prevention ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

OP0234 EFFICACY AND SAFETY OF BRODALUMAB, AN ANTI-INTERLEUKIN-17 RECEPTOR A MONOCLONAL ANTIBODY, IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: A 16 WEEK RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY

10.1136/annrheumdis-2019-eular.6888 ◽

2019 ◽

Cited By ~ 2

Author(s):

James Cheng-Chung Wei ◽

Tae-Hwan Kim ◽

Mitsumasa Kishimoto ◽

Takuya Morishige ◽

Naoki Ogusu ◽

...

Keyword(s):

Monoclonal Antibody ◽

Axial Spondyloarthritis ◽

Controlled Study ◽

Interleukin 17 ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

1.71 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (P302) ASSESSING THE EFFICACY AND SAFETY OF SPN-812 (EXTENDED-RELEASE VILOXAZINE) 200 AND 400MG FOR THE TREATMENT OF ADHD IN ADOLESCENTS

Journal of the American Academy of Child & Adolescent Psychiatry ◽

10.1016/j.jaac.2019.08.476 ◽

2019 ◽

Vol 58 (10) ◽

pp. S170

Author(s):

Azmi Nasser ◽

Gregory D. Busse ◽

Joseph Hull ◽

Fatima Chowdhry ◽

Toyin Adewole ◽

...

Keyword(s):

Extended Release ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

228. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study

Rheumatology ◽

10.1093/rheumatology/kev089.115 ◽

2015 ◽

Keyword(s):

Monoclonal Antibody ◽

Psoriatic Arthritis ◽

Radiographic Progression ◽

Safety Data ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Interleukin 17A

Download Full-text

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

Journal of Cystic Fibrosis ◽

10.1016/j.jcf.2015.12.004 ◽

2016 ◽

Vol 15 (4) ◽

pp. 495-502 ◽

Cited By ~ 33

Author(s):

Patrick A. Flume ◽

Donald R. VanDevanter ◽

Elizabeth E. Morgan ◽

Michael N. Dudley ◽

Jeffery S. Loutit ◽

...

Keyword(s):

Cystic Fibrosis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

1.72 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (P303) ASSESSING THE EFFICACY AND SAFETY OF SPN-812 (EXTENDED-RELEASE VILOXAZINE) 200 AND 400 MG FOR THE TREATMENT OF ADHD IN CHILDREN

Journal of the American Academy of Child & Adolescent Psychiatry ◽

10.1016/j.jaac.2019.08.483 ◽

2019 ◽

Vol 58 (10) ◽

pp. S170

Author(s):

Azmi Nasser ◽

Gregory D. Busse ◽

Joseph Hull ◽

Fatima Chowdhry ◽

Toyin Adewole ◽

...

Keyword(s):

Extended Release ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps8621 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS8621-TPS8621

Author(s):

Myron Stefan Czuczman ◽

Hans Knecht ◽

Rebecca Auer ◽

Joseph James McKendrick ◽

Neil Sun Chua ◽

...

Keyword(s):

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Previously Treated

Download Full-text

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps4132 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS4132-TPS4132 ◽

Cited By ~ 4

Author(s):

Johanna C. Bendell ◽

Alexander Starodub ◽

Zev A. Wainberg ◽

Meihua Wu ◽

Douglas Werner ◽

...

Keyword(s):

Gastroesophageal Junction ◽

Controlled Study ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Gastroesophageal Junction Adenocarcinoma ◽

First Line Treatment

Download Full-text